Dalane Kitzman to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications Dalane Kitzman has written about Clinical Trials, Phase II as Topic.
Connection Strength
0.343
-
Kitzman DW, Lewis GD, Pandey A, Borlaug BA, Sauer AJ, Litwin SE, Sharma K, Jorkasky DK, Khan S, Shah SJ. A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial. Eur J Heart Fail. 2024 Sep; 26(9):2013-2024.
Score: 0.214
-
Butler J, Hamo CE, Udelson JE, O'Connor C, Sabbah HN, Metra M, Shah SJ, Kitzman DW, Teerlink JR, Bernstein HS, Brooks G, Depre C, DeSouza MM, Dinh W, Donovan M, Frische-Danielson R, Frost RJ, Garza D, Gohring UM, Hellawell J, Hsia J, Ishihara S, Kay-Mugford P, Koglin J, Kozinn M, Larson CJ, Mayo M, Gan LM, Mugnier P, Mushonga S, Roessig L, Russo C, Salsali A, Satler C, Shi V, Ticho B, van der Laan M, Yancy C, Stockbridge N, Gheorghiade M. Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations. Circ Heart Fail. 2017 Apr; 10(4).
Score: 0.129